CVT Announces Agreement For Eye Q Capital To Purchase 6 Million Shares Of Common Stock At $1.00 Per Share.

Business Editors

EDMONTON, Alberta--(BUSINESS WIRE)--May 05, 2000

CV Technologies (CDNX:CVQ.)("CVT") announced today that it has signed an agreement with Eye Q Capital Corporation ("Eye Q") of Calgary to purchase 6 million new issue shares of CVT common stock, generating up to $6 million capital infusion for the Company.

Under the terms of the agreement, Eye Q is obligated to purchase 6 million shares in three lots over the next 9-11 months at a fixed price of $1.00. CVT is obligated to sell the first lot of two million shares to Eye Q, but CVT may elect to sell part or none of the additional two lots totaling 4 million shares depending on cash needs at that time. Further, Eye Q will be issued one warrant to purchase one additional share in CVT for $1.50, for each 3 shares purchased at $1.00, to a maximum 2 million warrants. The warrants must be exercised within twelve months of issuance. The sale of the final two lots of shares would require CVT shareholder approval. The terms of this agreement are subject to approval by the Canadian Venture Exchange.

Eye Q is in the process of merging with Brubuck Inc., the investment firm which currently owns approximately 16% of CVT's outstanding shares. Brubuck's president, Bruce Buchanan, commented that, "CVT is an industry leader in innovative proprietary technology which fits well with our investment strategy." He added, " CVT is poised to make a major impact in the healthcare industry as it commercializes its unique products and technology."

According to Jim Bruce, CVT's President & CEO, "This capital infusion will allow CVT to expedite its marketing programs, initiate additional FDA approved clinical trials, and to equip and market a proposed new laboratory facility for contract research utilizing our proprietary ChemBioPrint(TM) Technology."

About CV Technologies

CV Technologies (CVT) is an international science and technology Company which has developed and commercialized proprietary technology to identify, extract, and biologically standardize natural mixtures which deliver health benefits. CVT's research facility is located in Edmonton, Alberta. CVT has a staff of 40 people including 12 with Ph.D.'s and 2 M.D.'s. The Company maintains two full-scale laboratories and has access to 18 satellite facilities including offices in Boulder, Colorado and Hong Kong.

Utilizing the Company's ChemBioPrint(TM) technology, CVT scientists obtain specific chemical and biological profiles of natural mixtures, in addition to determining their mechanisms of action and optimal dosages. The result is the development of precise operating procedures for commercial production. All CVT products are certified effective, safe, biologically active, and consistent, batch-to-batch.

CV Technologies markets products in Canada under its HerbTech(R) brand name and supplies proprietary ingredients to national and international markets. The Company currently holds 18 patents, which includes 10 U.S. patents. An additional 29 patents are pending worldwide. Two Patent Cooperation Treaty applications have been filed.

James H. Bruce, Ken Broadfoot President and Chief Executive Officer Vice President CV Technologies Inc. CV Technologies Inc. 303/544-0229 780/432-0022

For further information, please contact:

Pfeiffer Public Relations, Inc. Jay Pfeiffer or Paul Savageau 303/393-7044 Fax: [phone] [e-mail]

This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "intends," "expects" and similar expressions are intended to identify forward-looking statements. Such risks and uncertainties include, but are not limited to the need for capital, changing market conditions, completion of clinical trials, patient enrollment rates, uncertainty of preclinical, retrospective and early clinical trial results, the establishment of manufacturing processes and new corporate alliances, the timely development, regulatory approval and market acceptance of the Company's products and other risks detailed from time to time in the Company's filings with Canadian securities authorities.

Canadian Venture Exchange trading symbol: CVQ "The Canadian Venture Exchange has neither approved nor disapproved the information contained herein." CV Technologies Inc., Suite 308, 8625 - 112 Street, Edmonton, Alberta CANADA T6G 1K8 Tel: [phone] Fax: [phone]